Lilly invests $9 Billion to Boost API Production at its new Manufacturing Site

Cover Image* (825px x 450px)No file chosen Eli Lilly and Company has recently announced that it has expanded its investment in its Lebanon, Indiana, manufacturing site from $3.7 billion to $9 billion, per the reports. The new $5.3 billion investment demonstrates Lilly’s commitment to enhancing its capacity to manufacture active pharmaceutical ingredients (API) for  Zepbound® (tirzepatide) injection and Mounjaro® (tirzepatide) injection to treat more adults with chronic diseases like obesity and type 2 diabetes. 

From 2020 till now, Lilly has invested over $16 billion to develop new U.S. and European manufacturing sites. The New locations outside Indiana include Research Triangle Park and Concord, North Carolina; Limerick, Ireland; and Alzey, Germany. Additionally, the company invested over $1.2 billion to update the existing manufacturing facilities in Indianapolis and recently acquired an injectable manufacturing facility from Nexus Pharmaceuticals. Altogether, the manufacturing investment sums up to more than $18 billion.

As its investment has expanded, there are job opportunities for nearly 900 full-time positions for engineers, scientists, operating personnel, and lab technicians. Besides this, more than 5,000 vacancies will be available during site construction.